Bachem stock holds steady with focus on peptide manufacturing. Published on 09/06/2026 at 18:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Bachem stock reflects investor interest in peptide-based pharmaceuticals as the company continues to expand its manufacturing capabilities for biotech and pharma customers. Bachem stock represents exposure to a specialized player in peptide and oligonucleotide manufacturing for the global pharmaceutical and biotechnology industry. The Swiss group (ISIN CH0012530207) has built its business around supplying active pharmaceutical ingredients and research-grade materials that underpin many modern therapies. Peptide manufacturing as a core business. Bachem focuses on the development and large-scale production of synthetic peptides and related molecules that are used as active ingredients in drugs as well as in preclinical and clinical research. For investors, this means the company's fortunes are closely tied to progress in peptide-based therapeutics and to long-term supply agreements with pharma partners. In recent years, the broader market for peptide medicines has grown as more drug makers pursue highly targeted treatments, for example in metabolic diseases, oncology and rare conditions. Bachem has responded by expanding capacity, investing in new plants and process technologies, and positioning itself as a strategic partner for both large pharma and emerging biotech customers. Operational scale and customer base. The company operates multiple production sites in Europe and North America, which allows it to supply customers across different regions and manage regulatory requirements in major markets. Its customer base typically includes large pharmaceutical companies, generic drug producers and specialized biotech firms that rely on a steady, high-quality supply of complex peptide ingredients. Because peptide synthesis is technically demanding and subject to strict quality standards, Bachem's ability to run efficient, compliant manufacturing at scale is central to its competitive position. The group's pipeline of customer projects and the mix between commercial APIs and research services are key drivers for revenue and profitability over time. More on Bachem as an investment. Further articles and regulatory disclosures help investors follow how Bachem stock reacts to new contracts, capacity expansions and financial results. Representative product: peptide active ingredients. One representative area of Bachem's portfolio is the supply of peptide active pharmaceutical ingredients manufactured under strict good manufacturing practice standards. These ingredients are used in approved medicines and in clinical-stage compounds, making reliability and regulatory compliance crucial for customers. Stock as a way to participate. For investors, Bachem stock offers a way to participate in the long-term growth of peptide-based therapies and in the company's role as a specialized contract manufacturer. The stock is typically traded on Swiss exchanges and reflects expectations about future demand for complex peptide ingredients and the company's ability to translate that demand into stable revenue and earnings. Bachem at a glance. * Company: Bachem Holding AG * ISIN: CH0012530207 * Ticker: BACN * Trading venue: SIX Swiss Exchange * Sector / Industry: Health Care / Pharmaceuticals * Index membership: SPI Follow Bachem on social platforms. Sponsored Ad Bachem stock: new analysis - 15 september. Fresh Bachem information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | CH0012530207 | BACHEM | boerse | 70060733 | bgmi

Bachem case study presents new method for verifying oligonucleotide peak purity. news-releases Bachem AG August 26th 2026 Bubendorf, Switzerland - A new case study from leading CDMO Bachem details a two-dimensional liquid chromatography-mass spectrometry workflow for verifying the purity of oligonucleotide peaks separated by strong anion exchange (SAX) chromatography. The workflow combines SAX fraction collection with mass spectrometry-compatible ion-pair reversed-phase (IP-RP) chromatography, enabling potential co-eluting impurities within apparently pure SAX peaks to be identified. Overcoming an analytical challenge. This latest advance forms part of Bachem's continuing drive toward more accurate analytical characterization throughout oligonucleotide development. It supports impurity profiling and stability assessment, ultimately contributing to the delivery of high-quality active pharmaceutical ingredients (APIs). Strong anion exchange liquid chromatography and mass spectrometry are two powerful analytical tools for characterizing oligonucleotides. SAX is widely used as an orthogonal method to support the purity assessment of oligonucleotide APIs because it separates analytes differently from IP-RP chromatography. However, the non-volatile salts used in SAX mobile phases prevent direct coupling to mass spectrometry. This makes it difficult to determine whether a seemingly pure UV-detected peak contains co-eluting impurities. 2D SAX-IP-RP-MS workflow. To address this analytical challenge, Bachem has developed a two-dimensional SAX-IP-RP-MS workflow. Bachem describes this as the first method to bring mass spectrometric detection to SAX-separated material, making it possible to verify the peak purity achieved by a SAX method. The workflow involves collecting individual SAX fractions and reanalyzing them using MS-compatible IP-RP chromatography. This enables MS-based assessment of peak purity and provides additional confidence in SAX method performance. siRNA case study. The case study demonstrates the application of the method to a representative duplex small interfering RNA (siRNA) API. The workflow was used to evaluate SAX main peaks that would have been classified as pure based on UV detection alone. The paper explains: * Why UV detection alone may not be sufficient to confirm the purity of SAX main peaks and how co-eluting impurities can remain undetected * How the 2D SAX-IP-RP-MS workflow enables MS-based evaluation of SAX peak purity * How the workflow was applied to a duplex siRNA, revealing PS | PO, methylation, and des-/endo- species beneath the antisense SAX main peak * Why the method is positioned as a development and verification tool that strengthens the routine release strategy without changing it * How 2D SAX-IP-RP-MS fits within Bachem's broader analytical capabilities for oligonucleotide development programs The case study can be downloaded from the Bachem Knowledge Hub via the link under Resources. About Bachem. Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has more than 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. Resources. Case study. Pushing the Boundaries - MCSGP for efficiency and sustainability FREE DOWNLOAD Bachem AG. Contact Information Address: Hauptstrasse 144, 4416, Bubendorf, Switzerland Telephone No: +41 58 595 2021 Contact Bachem AG. Simply fill out the form below to contact Bachem AG now.

Bachem slightly lowers its sales forecast. Abo FuW initial assessment of half-year figures Bachem slightly lowers its sales forecast. The pharmaceutical contract manufacturer recorded 4.3% more revenue in the first half. The jump expected for the second half of the year is now likely to be at the lower end of the previously expected range. Updated 4 hours ago Initial assessment by Rupen Boyadjian at 8:10 a.m. As expected, Bachem grew only modestly in the first half of the year, with revenue rising 4.3% to CHF 326.4 million. In local currencies (LC), growth was +7.3%. Earnings were weighed down by costs for the commissioning of the new production building K for large volumes of peptides. Operating profit at the EBITDA level fell 9% (-4.2% LC) to CHF 82.8 million, but net profit still rose slightly to CHF 50.3 million (H1 2025: CHF 50.1 million).